The P-II clinical trial evaluating the safety & tolerability of BX1000 (at 3 doses) vs rocuronium for the neuromuscular blockade is expected to enrol ~80 adult patients undergoing elective surgery. Baudax expects to combine BX1000 + BX3000 (expected IND filing in 2023) for the precise control of timing under neuromuscular paralysis for surgical patients
The interim analysis evaluated the patient’s intubating conditions post administering BX1000 in a blinded manner. In the 20-patient cohort, 5 patients per group received one of the study medications
The results depicted that all 20 patients met the 1EP of good/excellent intubating conditions at 60sec. out of which 20 were intubated following assessment at 60sec. & 1 at 90sec.
Ref: GlobeNewswire | Image: Baudax
Related News:- Baudax Bio’s Anjeso Receives the US FDA’s Approval to Manage Moderate to Severe Pain
